Understand the source comparison
How to Use Peptides for IBS: Comparison of Protocol Options
Before starting any peptide protocol, understand the trade-offs between compounds, administration routes, and dosing schedules. KPV NF-κB inhibition, cytokine suppression (TNF-α, IL-6) IBS-D, IBS-M 500 mcg/day Once daily (morning) Symptom reduction 3–4 weeks,
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before starting any peptide protocol, understand the trade-offs between compounds, administration routes, and dosing schedules.
- KPV
- NF-κB inhibition, cytokine suppression (TNF-α, IL-6)
- IBS-D, IBS-M
- 500 mcg/day
- Once daily (morning)
- Symptom reduction 3–4 weeks, full effect 8–10 weeks
- First-line for diarrhea-predominant IBS. Strongest anti-inflammatory data
- BPC-157
- VEGF upregulation, mucosal angiogenesis, epithelial repair
- IBS-C, post-inflammatory recovery
- 250–500 mcg/day
- Once or twice daily
- Mucosal repair visible 4–6 weeks, symptom resolution 8–12 weeks
- Best for constipation and healing-phase protocols. Weaker acute anti-inflammatory effect than KPV
- Oral KPV (experimental)
- Same as subcutaneous but degraded by gastric enzymes
- IBS-D (low efficacy)
- 1–2 mg/day
- Once daily with food
- Variable. Limited bioavailability
- Not recommended. Subcutaneous route delivers 3–5× higher tissue concentration
- Combination (KPV + BPC-157)
- Dual anti-inflammatory + repair signaling
- IBS-M, treatment-refractory cases
- 500 mcg KPV + 250 mcg BPC-157 daily
- KPV morning, BPC-157 evening
- Fastest symptom resolution. 6–8 weeks typical
- Used in research settings for refractory IBS. Requires close monitoring